215 related articles for article (PubMed ID: 35304903)
21. Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases.
Xia LY; Hu QL; Zhang J; Xu WY; Li XS
World J Surg Oncol; 2020 Jun; 18(1):129. PubMed ID: 32539858
[TBL] [Abstract][Full Text] [Related]
22. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
23. Analysis of neoadjuvant chemotherapy for breast cancer: a 20-year retrospective analysis of patients of a single institution.
Chen D; Wang Q; Dong M; Chen F; Huang A; Chen C; Lu Y; Zhao W; Wang L
BMC Cancer; 2023 Oct; 23(1):984. PubMed ID: 37845617
[TBL] [Abstract][Full Text] [Related]
24. Neutrophil-lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer.
Chae S; Kang KM; Kim HJ; Kang E; Park SY; Kim JH; Kim SH; Kim SW; Kim EK
Curr Oncol; 2018 Apr; 25(2):e113-e119. PubMed ID: 29719435
[TBL] [Abstract][Full Text] [Related]
25. Monitoring Serum VEGF in Neoadjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer: A New Strategy for Early Prediction of Treatment Response and Patient Survival.
Wang RX; Chen S; Huang L; Zhou Y; Shao ZM
Oncologist; 2019 Jun; 24(6):753-761. PubMed ID: 30126858
[TBL] [Abstract][Full Text] [Related]
26. Value of CXCL8-CXCR1/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: a retrospective pilot study.
Wang RX; Ji P; Gong Y; Shao ZM; Chen S
Breast Cancer Res Treat; 2020 Jun; 181(3):561-570. PubMed ID: 32361849
[TBL] [Abstract][Full Text] [Related]
27. Thrombospondin 2 is a Functional Predictive and Prognostic Biomarker for Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy.
Lin Y; Lin E; Li Y; Chen X; Chen M; Huang J; Guo W; Chen L; Wu L; Zhang X; Zhang W; Jin X; Zhang J; Fu F; Wang C
Pathol Oncol Res; 2022; 28():1610559. PubMed ID: 36405394
[No Abstract] [Full Text] [Related]
28. Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.
Gamucci T; Pizzuti L; Sperduti I; Mentuccia L; Vaccaro A; Moscetti L; Marchetti P; Carbognin L; Michelotti A; Iezzi L; Cassano A; Grassadonia A; Astone A; Botticelli A; Magnolfi E; Di Lauro L; Sergi D; Fuso P; Tinari N; Barba M; Maugeri-Saccà M; Landucci E; Conti F; Sanguineti G; De Tursi M; Iafrate G; Giordano A; Ciliberto G; Natoli C; Vici P
J Cell Physiol; 2018 Mar; 233(3):2313-2323. PubMed ID: 28710865
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Value of Immunohistochemistry-based Subtyping Before and After Neoadjuvant Chemotherapy in Patients with Triple-negative Breast Cancer.
Wu L; Chen M; Lin Y; Zeng B; Guo W; Chen L; Li Y; Yu L; Li J; Chen X; Zhang W; Li S; Cai W; Zhang K; Jin X; Huang J; Lin Q; Yang Y; Fu F; Wang C
Am J Surg Pathol; 2024 Jan; 48(1):27-35. PubMed ID: 38117286
[TBL] [Abstract][Full Text] [Related]
30. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Loibl S; Müller BM; Roller M; Denkert C; Komor M; Schlüns K; Blohmer JU; Budczies J; Gerber B; Noske A; du Bois A; Weichert W; Jackisch C; Dietel M; Richter K; Kaufmann M; von Minckwitz G
Breast Cancer Res; 2009; 11(5):R69. PubMed ID: 19758440
[TBL] [Abstract][Full Text] [Related]
31. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy.
Loibl S; Müller BM; von Minckwitz G; Schwabe M; Roller M; Darb-Esfahani S; Ataseven B; du Bois A; Fissler-Eckhoff A; Gerber B; Kulmer U; Alles JU; Mehta K; Denkert C
Breast Cancer Res Treat; 2011 Nov; 130(2):477-87. PubMed ID: 21837479
[TBL] [Abstract][Full Text] [Related]
32. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
[TBL] [Abstract][Full Text] [Related]
33. Patients achieved pCR during neoadjuvant chemotherapy had better outcome than adjuvant chemotherapy setting in breast cancer: A comparative study.
Chen J; Jin L; Chen L; Bian Z; Li Z; Cao S; Zhou J; Xu L; Zhao W; Wang Q
Cancer Treat Res Commun; 2023; 36():100719. PubMed ID: 37187018
[TBL] [Abstract][Full Text] [Related]
34. [The expression of Plakoglobin in residual cancer after neoadjuvant chemotherapy for breast cancer and its prognostic impact on patients].
Li Y; Guo L; Guo CY; Lei CQ; Zhang K; Wang NC; Wang ZZ; Xuan LX
Zhonghua Zhong Liu Za Zhi; 2023 Dec; 45(12):1057-1064. PubMed ID: 38110314
[No Abstract] [Full Text] [Related]
35. Predictive and prognostic value of PDL1 protein expression in breast cancer patients in neoadjuvant setting.
Wu Z; Zhang L; Peng J; Xu S; Zhou L; Lin Y; Wang Y; Lu J; Yin W; Lu J
Cancer Biol Ther; 2019; 20(6):941-947. PubMed ID: 30866717
[TBL] [Abstract][Full Text] [Related]
36. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy.
Chen L; Kong X; Wang Z; Wang X; Fang Y; Wang J
J Cell Mol Med; 2020 Mar; 24(5):2993-3021. PubMed ID: 31989747
[TBL] [Abstract][Full Text] [Related]
37. Platinum chemotherapy for early triple-negative breast cancer.
Mason SR; Willson ML; Egger SJ; Beith J; Dear RF; Goodwin A
Breast; 2024 Jun; 75():103712. PubMed ID: 38492276
[TBL] [Abstract][Full Text] [Related]
38. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
[TBL] [Abstract][Full Text] [Related]
39. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?
Dülgar Ö; Öven BB; Atcı MM; Arıkan R; Ay S; Ayhan M; Selvi O; Ozyukseler DT; Bayram E; Özcan E; Yasin Aİ; Gümüş M
Expert Rev Anticancer Ther; 2022 Jul; 22(7):773-780. PubMed ID: 35543015
[TBL] [Abstract][Full Text] [Related]
40. Preoperative Breast Immune Prognostic Index as Prognostic Factor Predicts the Clinical Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
Chen L; Kong X; Huang S; Su Z; Zhu M; Fang Y; Zhang L; Li X; Wang J
Front Immunol; 2022; 13():831848. PubMed ID: 35320931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
